The North American opioid epidemic: opportunities and challenges for clinical laboratories

References

• Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344–350.
   PubMed Web of Science ®Google Scholar
• Vearrier D, Grundmann O. Clinical pharmacology, toxicity, and abuse potential of opioids. J Clin Pharmacol. 2021;61(Suppl 2):S70–S88.
   PubMedGoogle Scholar
• CDC. Vital statistics rapid release. Provisional drug overdose death counts; 2021 [cited 2021 Nov 24]. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
   Google Scholar
• Han Y, Yan W, Zheng Y, et al. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl Psychiatry. 2019;9(1):282.
   PubMed Web of Science ®Google Scholar
• Hauser W, Buchser E, Finn DP, et al. Is Europe also facing an opioid crisis?-a survey of european pain federation chapters. Eur J Pain. 2021;25(8):1760–1769.
   PubMed Web of Science ®Google Scholar
• Alsabbagh MW, Chang F, Cooke M, et al. National trends in population rates of opioid-related mortality, hospitalization and emergency department visits in Canada between 2000 and 2017. A population-based study. Addiction. 2021;116(12):3482–3493.
   PubMedGoogle Scholar
• Gomes T, Kitchen SA, Murray R. Measuring the burden of opioid-related mortality in Ontario, Canada, during the COVID-19 pandemic. JAMA Netw Open. 2021;4(5):e2112865.
   PubMedGoogle Scholar
• Jannetto PJ. The North american opioid Epidemic. Ther Drug Monit. 2021;43(1):1–5.
   PubMed Web of Science ®Google Scholar
• Jannetto PJ, Helander A, Garg U, et al. The fentanyl epidemic and evolution of fentanyl analogs in the United States and the european union. Clin Chem. 2019;65(2):242–253.
   PubMed Web of Science ®Google Scholar
• McMillin GA, Johnson-Davis KL, Kelly BN, et al. Impact of the opioid epidemic on drug testing. Ther Drug Monit. 2021;43(1):14–24.
   PubMedGoogle Scholar
• Nguyen L, Lander LR, O'Grady KE, et al. Treating women with opioid use disorder during pregnancy in Appalachia: initial neonatal outcomes following buprenorphine + naloxone exposure. Am J Addict. 2018;27(2):92–96.
   PubMedGoogle Scholar
• Prekupec MP, Mansky PA, Baumann MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med. 2017;11(4):256–265.
   PubMed Web of Science ®Google Scholar
• Chua IS, Ransohoff JR, Ehrlich O, et al. Laboratory-generated urine toxicology interpretations: a mixed methods study. Pain Physician. 2021;24(2):E191–E201.
   PubMedGoogle Scholar
• Tacker DH, Adelanwa A, Pearson N, et al. Fentanyl quality assurance project prompted change in clinical workflow and test configurations. J Appl Lab Med. 2021;6(1):93–100.
   PubMedGoogle Scholar
• Wharton RE, Casbohm J, Hoffmaster R, et al. Detection of 30 fentanyl analogs by commercial immunoassay kits. J Anal Toxicol. 2021;45(2):111–116.
   PubMedGoogle Scholar
• Argoff CE, Alford DP, Fudin J, et al. Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med. 2018;19(1):97–117.
   PubMed Web of Science ®Google Scholar
• Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11(3):163–173.
   PubMedGoogle Scholar
• Cheriyan T, Mandyam SA, Patel AS, et al. The need for evidence-based urine drug testing protocols to improve outcomes. Pain Pract. 2021;21(8):1001–1002.
   PubMedGoogle Scholar
• Chua I, Petrides AK, Schiff GD, et al. Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results. J Gen Intern Med. 2020;35(1):283–290.
   PubMed Web of Science ®Google Scholar
• Keller MS, Jusufagic A, Nuckols TK, et al. How do clinicians of different specialties perceive and use opioid risk mitigation strategies? A qualitative study. Subst Use Misuse. 2021;56(9):1352–1362.
   PubMedGoogle Scholar
• Taha SA, Westra JR, Raji MA, et al. Trends in urine drug testing among long-term opioid users, 2012–2018. Am J Prev Med. 2021;60(4):546–551.
   PubMedGoogle Scholar
• CLSI. Laboratory support for pain management programs. 1st ed. (CLSI guideline C63). Wayne PA: Clinical Laboratory Standards Institute; 2018.
   Google Scholar
• Jannetto PJ, Bratanow NC, Clark WA, et al. Executive summary: American Association of Clinical Chemistry laboratory medicine practice guideline-using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2(4):489–526.
   PubMedGoogle Scholar
• Wish ED, Billing AS, Heine K, et al. Toward a national system of expanded testing of existing urine specimens: the drug outbreak testing service (DOTS). Subst Use Misuse. 2021;56(11):1576–1585.
   PubMed Web of Science ®Google Scholar
• SAMHSA. Medical review officer guidance manual for federal workplace drug testing programs; 2017 [cited 2021 Nov 24]. Available from: https://www.samhsa.gov/sites/default/files/workplace/mro-guidance-manual-oct2017_2.pdf
   Google Scholar
• Guerrieri D, Kjellqvist F, Kronstrand R, et al. Validation and cross-reactivity data for fentanyl analogs with the immunalysis fentanyl ELISA. J Anal Toxicol. 2019;43(1):18–24.
   PubMedGoogle Scholar
• Krasowski MD, McMillin GA, Melanson SEF, et al. Interpretation and utility of drug of abuse screening immunoassays: insights from laboratory drug testing proficiency surveys. Arch Pathol Lab Med. 2020;144(2):177–184.
   PubMedGoogle Scholar
• Tang MS, Lloyd M, Williams M, et al. Performance evaluation of an automated fentanyl immunoassay. J Appl Lab Med. 2021;6(5):1192–1201.
   PubMedGoogle Scholar
• Li Z, Wang P. Point-of-care drug of abuse testing in the opioid epidemic. Arch Pathol Lab Med. 2020;144(11):1325–1334.
   PubMedGoogle Scholar
• Kapur BM, Aleksa K. What the lab can and cannot do: clinical interpretation of drug testing results. Crit Rev Clin Lab Sci. 2020;57(8):548–585.
   PubMed Web of Science ®Google Scholar
• Abbott DL, Limoges JF, Virkler KJ, et al. ELISA screens for fentanyl in urine are susceptible to false-positives in high concentration methamphetamine samples. J Anal Toxicol. 2021. DOI:https://doi.org/10.1093/jat/bkab033
   Google Scholar
• Shaikh S, Hull MJ, Bishop KA, et al. Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine. J Anal Toxicol. 2008;32(5):339–343.
   PubMedGoogle Scholar
• Wang BT, Colby JM, Wu AH, et al. Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay. J Anal Toxicol. 2014;38(9):672–675.
   PubMed Web of Science ®Google Scholar
• Dixon RB, Dasgupta A. Suitability of the DRI hydrocodone/hydromorphone immunoassay in the clinical environment at a lower cutoff: validation with LC-MS/MS analysis. Ther Drug Monit. 2016;38(6):787–790.
   PubMedGoogle Scholar
• Ceasar R, Chang J, Zamora K, et al. Primary care providers' experiences with urine toxicology tests to manage prescription opioid misuse and substance use among chronic noncancer pain patients in safety net health care settings. Subst Abus. 2016;37(1):154–160.
   PubMed Web of Science ®Google Scholar
• Moeller KE, Bates J, Melton BL. Assessing pharmacy students' knowledge and perceptions of urine drug testing following a pharmacy skills laboratory. Curr Pharm Teach Learn. 2021;13(5):530–535.
   PubMedGoogle Scholar
• Suzuki J, Garayalde S, Dodoo M, et al. Psychiatry residents' and fellows' confidence and knowledge in interpreting urine drug testing results related to opioids. Subst Abus. 2018;39(4):518–521.
   PubMed Web of Science ®Google Scholar
• Durback LF, Scharman EJ, Brown BS. Emergency physicians perceptions of drug screens at their own hospitals. Vet Hum Toxicol. 1998;40(4):234–237.
   PubMedGoogle Scholar
• Beck O, Carlsson S, Tusic M, et al. Laboratory and clinical evaluation of on-site urine drug testing. Scand J Clin Lab Invest. 2014;74(8):681–686.
   PubMed Web of Science ®Google Scholar
• Wu AH. Limitations of point-of-care testing in the ED or ICU: a role for regional centralized toxicology laboratories. Clin Pharmacol Ther. 2010;88(3):295–298.
   PubMed Web of Science ®Google Scholar
• Gencheva R, Petrides A, Kantartjis M, et al. Clinical benefits of direct-to-definitive testing for monitoring compliance in pain management. Pain Physician. 2018;21(6):E583–E592.
   PubMedGoogle Scholar
• Kahl KW, Seither JZ, Reidy LJ. LC-MS-MS vs ELISA: Validation of a comprehensive urine toxicology screen by LC-MS-MS and a comparison of 100 forensic specimens. J Anal Toxicol. 2019;43(9):734–745.
   PubMed Web of Science ®Google Scholar
• McMillin GA, Marin SJ, Johnson-Davis KL, et al. A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol. 2015;143(2):234–240.
   PubMed Web of Science ®Google Scholar
• Solbeck P, Woodall KL, Martin TL. Strategic decision-making by a forensic toxicology laboratory in response to an emerging NPS: detection, quantitation and interpretation of carfentanil in death investigations in Ontario, Canada, July 2017 to June 2018. J Anal Toxicol. 2021;45(8):813–819.
   PubMedGoogle Scholar
• Rosano TG, Wood M, Hooten WM, et al. Application and clinical value of definitive drug monitoring in pain management and addiction medicine. Pain Med. 2021. DOI:https://doi.org/10.1093/pm/pnab303
   Google Scholar
• Allen DR, McWhinney BC. Quadrupole time-of-flight mass spectrometry: a paradigm shift in toxicology screening applications. Clin Biochem Rev. 2019;40(3):135–146.
   PubMedGoogle Scholar
• Colby JM, Thoren KL, Lynch KL. Optimization and validation of high-resolution mass spectrometry data analysis parameters. J Anal Toxicol. 2017;41(1):1–5.
   PubMedGoogle Scholar
• Salomone A, Di Corcia D, Negri P, et al. Targeted and untargeted detection of fentanyl analogues and their metabolites in hair by means of UHPLC-QTOF-HRMS. Anal Bioanal Chem. 2021;413(1):225–233.
   PubMed Web of Science ®Google Scholar
• Danso D, Langman LJ, Jannetto PJ. Interference testing and isobaric compounds: is your mass spectrometry-based assay as good as you think it is? J Appl Lab Med. 2018;2(4):666–668.
   PubMedGoogle Scholar
• Van Wijk XMR, Goodnough R, Colby JM. Mass spectrometry in emergency toxicology: current state and future applications. Crit Rev Clin Lab Sci. 2019;56(4):225–238.
   PubMed Web of Science ®Google Scholar
• Scientific working group for forensic toxicology (SWGTOX) standard practices for method validation in forensic toxicology. J Anal Toxicol. 2013;37(7):452–474.
   PubMed Web of Science ®Google Scholar
• Garneau B, Desharnais B, Beauchamp-Dore A, et al. Challenges related to three cases of fatal intoxication to multiple novel synthetic opioids. J Anal Toxicol. 2020;44(1):86–91.
   PubMedGoogle Scholar
• Fu S. Adulterants in urine drug testing. Adv Clin Chem. 2016;76:123–163.
   PubMed Web of Science ®Google Scholar
• Raouf M, Bettinger JJ, Fudin J. A practical guide to urine drug monitoring. Fed Pract. 2018;35(4):38–44.
   PubMedGoogle Scholar
• Warrington JS, Warrington GS, Francis-Fath S, et al. Urinary buprenorphine, norbuprenorphine and naloxone concentrations and ratios: review and potential clinical implications. J Addict Med. 2020;14(6):e344–e349.
   PubMedGoogle Scholar
• Lee D, Bazydlo LA, Reisfield GM, et al. Urine spiking in a pain medicine clinic: an attempt to simulate adherence. Pain Med. 2015;16(7):1449–1451.
   PubMedGoogle Scholar
• Hurford M. Appropriate use of drug testing in clinical addiction medicine: American Society of Addiction Medicine; 2017 [cited 2022 Jan 21]. Available from: https://sitefinitystorage.blob.core.windows.net/sitefinity-production-blobs/docs/default-source/guidelines/the-asam-appropriate-use-of-drug-testing-in-clinical-addiction-medicine-full-document.pdf?sfvrsn=700a7bc2_0
   Google Scholar
• Rosano TG, Ohouo PY, Wood M. Application of high-resolution UPLC-MSE/TOF confirmation in forensic urine drug screening by UPLC-MS/MS. J Anal Toxicol. 2019;43(5):353–363.
   PubMedGoogle Scholar
• CMS. Proper coding for specimen validity testing billed in combination with drug testing: Centers for Medicare and Medicaid Services; 2018 [cited 2021 Nov 8]. Available from: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE18001.pdf
   Google Scholar
• Arthur JA. Urine drug testing in cancer pain management. Oncologist. 2020;25(2):99–104.
   PubMed Web of Science ®Google Scholar
• Griswold MK, Chai PR, Krotulski AJ, et al. A novel oral fluid assay (LC-QTOF-MS) for the detection of fentanyl and clandestine opioids in oral fluid after reported heroin overdose. J Med Toxicol. 2017;13(4):287–292.
   PubMed Web of Science ®Google Scholar
• Stellpflug SJ, Cole JB, Greller HA. Urine drug screens in the emergency department: the best test may be no test at all. J Emerg Nurs. 2020;46(6):923–931.
   PubMedGoogle Scholar
• Doyle K, Strathmann FG. Cost and efficacy assessment of an alternative medication compliance urine drug testing strategy. Pain Med. 2017;18(2):307–315.
   PubMedGoogle Scholar
• Day-Storms JJ, Kren EM, Bush J, et al. The hidden cost of the opioid epidemic in the United States: drug screening in insurance claims. Ther Drug Monit. 2021;43(1):25–34.
   PubMedGoogle Scholar
• Bertholf RL, Reisfield GM. Opioid use disorders, medication-assisted treatment, and the role of the laboratory. Lab Med. 2017;48(4):e57–e61.
   PubMedGoogle Scholar
• Melanson SE, Ptolemy AS, Wasan AD. Optimizing urine drug testing for monitoring medication compliance in pain management. Pain Med. 2013;14(12):1813–1820.
   PubMedGoogle Scholar
• Sandbrink F, Oliva EM, McMullen TL, et al. Opioid prescribing and opioid risk mitigation strategies in the veterans health administration. J Gen Intern Med. 2020;35(Suppl 3):927–934.
   PubMedGoogle Scholar
• Kerensky T, LaRochelle M, Fan SL, et al. Non-prescription fentanyl positive toxicology: prevalence, positive predictive value of fentanyl immunoassay screening, and description of co-substance use. J Addict Med. 2021;15(2):150–154.
   PubMedGoogle Scholar
• Krock K, Pesce A, Ritz D, et al. Lower cutoffs for LC-MS/MS urine drug testing indicates better patient compliance. Pain Physician. 2017;20(7):E1107–E1113.
   PubMedGoogle Scholar
• Darragh A, Snyder ML, Ptolemy AS, et al. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain. Pain Physician. 2014;17(4):359–366.
   PubMedGoogle Scholar
• Snyder ML, Darragh A, Flood JG, et al. Improved buprenorphine immunoassay performance after urine treatment with β-glucuronidase. J Anal Toxicol. 2014;38(6):375–379.
   PubMedGoogle Scholar
• Picht F, Beck O, Bottcher M. Evaluation of an on-site test device for the heroin metabolite 6-acetylmorphine in urine. Drug Test Anal. 2019;11(3):536–540.
   PubMedGoogle Scholar
• CAP LAP. Chemistry and toxicology checklist CHM.28875 effective 17 September 2019. College of American Pathologists Laboratory Accreditation Program; 2019.
   Google Scholar
• Li Z, Chen H, Feng S, et al. Development and clinical validation of a sensitive lateral flow assay for rapid urine fentanyl screening in the emergency department. Clin Chem. 2020;66(2):324–332.
   PubMedGoogle Scholar
• Amlani A, McKee G, Khamis N, et al. Why the FUSS (fentanyl urine screen study)? a cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J. 2015;12:54.
   PubMed Web of Science ®Google Scholar
• Martinez S, Jones JD, Brandt L, et al. The increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City. Am J Addict. 2021;30(1):65–71.
   PubMedGoogle Scholar
• Nichols JH. Verification of method performance for clinical laboratories. Adv Clin Chem. 2009;47:121–137.
   PubMed Web of Science ®Google Scholar
• Genzen JR. Regulation of laboratory-developed tests. Am J Clin Pathol. 2019;152(2):122–131.
   PubMed Web of Science ®Google Scholar
• Johnson WG, Marchant GE. Legislating in the time of a pandemic: window of opportunity or invitation for recklessness? J Law Biosci. 2020;7(1):lsaa042.
   PubMedGoogle Scholar
• Graden KC, Bennett SA, Delaney SR, et al. A high-level overview of the regulations surrounding a clinical laboratory and upcoming regulatory challenges for laboratory developed tests. Lab Med. 2021;52(4):315–328.
   PubMedGoogle Scholar
• Huang R, Lasiter L, Bard A, et al. National maintenance cost for precision diagnostics under the verifying accurate leading-edge in vitro clinical test development (VALID) act of 2020. JCO Oncol Pract. 2021;17(11):e1763–e1773.
   PubMedGoogle Scholar
• Chhabra N, Rizvanolli L, Rasin A, et al. A cross-sectional analysis of fentanyl analog exposures among living patients. Am J Drug Alcohol Abuse. 2021;47(3):344–349.
   PubMedGoogle Scholar
• Thoren KL, Colby JM, Shugarts SB, et al. Comparison of information-dependent acquisition on a tandem quadrupole TOF vs a triple quadrupole linear ion trap mass spectrometer for broad-spectrum drug screening. Clin Chem. 2016;62(1):170–178.
   PubMed Web of Science ®Google Scholar
• Chakravarthy K, Goel A, Jeha GM, et al. Review of the current state of urine drug testing in chronic pain: Still effective as a clinical tool and curbing abuse, or an arcane test? Curr Pain Headache Rep. 2021;25(2):12.
   PubMedGoogle Scholar
• Blum K, Han D, Femino J, et al. Systematic evaluation of "compliance" to prescribed treatment medications and "abstinence" from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLOS One. 2014;9(9):e104275.
   PubMedGoogle Scholar
• Blum K, Han D, Modestino EJ, et al. A systematic, intensive statistical investigation of data from the comprehensive analysis of reported drugs (CARD) for compliance and illicit opioid abstinence in substance addiction treatment with buprenorphine/naloxone. Subst Use Misuse. 2018;53(2):220–229.
   PubMed Web of Science ®Google Scholar
• Munoz-Munoz AC, Pekol T, Schubring D, et al. Identification of novel opioid interferences using high-resolution mass spectrometry. J Anal Toxicol. 2018;42(1):6–16.
   PubMedGoogle Scholar
• Budelier MM, Franks CE, Farnsworth CW, et al. Detecting fentanyl analogs in urine using precursor ion scan mode. J Anal Toxicol. 2021. DOI:https://doi.org/10.1093/jat/bkab002
   Google Scholar
• Hughes MM, Atayee RS, Best BM, et al. Observations on the metabolism of morphine to hydromorphone in pain patients. J Anal Toxicol. 2012;36(4):250–256.
   PubMed Web of Science ®Google Scholar
• Garneau B, Desharnais B, Laquerre J, et al. A comprehensive analytical process, from NPS threat identification to systematic screening: method validation and one-year prevalence study. Forensic Sci Int. 2021;318:110595.
   PubMedGoogle Scholar
• Mojica MA, Carter MD, Isenberg SL, et al. Designing traceable opioid material§ kits to improve laboratory testing during the U.S. opioid overdose crisis. Toxicol Lett. 2019;317:53–58.
   PubMedGoogle Scholar
• Krajewski LC, Swanson KD, Bragg WA, et al. Application of the fentanyl analog screening kit toward the identification of emerging synthetic opioids in human plasma and urine by LC-QTOF. Toxicol Lett. 2020;320:87–94.
   PubMed Web of Science ®Google Scholar
• CDC. Traceable opioid material kits to improve laboratory detection of synthetic opioids in the US; 2019 [cited 2021 Nov 25]. Available from: https://www.cdc.gov/nceh/dls/erb_opioid_kits.html
   Google Scholar
• Kirane H, Drits E, Ahn S, et al. Addressing the opioid crisis: an assessment of clinicians' training experience, practices, and attitudes within a large healthcare organization. J Opioid Manag. 2019;15(3):193–204.
   PubMedGoogle Scholar
• Schepis TS, Wilens TE, McCabe SE. Prescription drug misuse: Sources of controlled medications in adolescents. J Am Acad Child Adolesc Psychiatry. 2019;58(7):670–680 e4.
   PubMed Web of Science ®Google Scholar
• McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-conception and maturation. Drug Alcohol Depend. 2017;178:176–187.
   PubMed Web of Science ®Google Scholar
• DPA. Drug policy alliance: supervised consumption services; 2018 [cited 2021 Nov 25]. Available from: https://drugpolicy.org/resource/supervised-consumption-services
   Google Scholar
• Milloy MJ, Kerr T, Tyndall M, et al. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLOS One. 2008;3(10):e3351.
   PubMed Web of Science ®Google Scholar
• Salmon AM, van Beek I, Amin J, et al. High HIV testing and low HIV prevalence among injecting drug users attending the Sydney medically supervised injecting Centre. Aust N Z J Public Health. 2009;33(3):280–283.
   PubMedGoogle Scholar
• Kral AH, Lambdin BH, Wenger LD, et al. Evaluation of an unsanctioned safe consumption site in the United States. N Engl J Med. 2020;383(6):589–590.
   PubMed Web of Science ®Google Scholar
• Mema SC, Sage C, Popoff S, et al. Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia. Harm Reduct J. 2018;15(1):19.
   PubMedGoogle Scholar
• Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59–66.
   PubMed Web of Science ®Google Scholar
• Strike C, Watson TM. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. Int J Drug Policy. 2019;71:178–182.
   PubMed Web of Science ®Google Scholar
• Maghsoudi N. Comparing models of drug checking services in Canada: Centre on Drug Policy Evaluation; 2018 [cited 2021 Nov 25]. Available from: https://cdpe.org/wp-content/uploads/2020/04/Comparing-Models-of-DCS-in-Canada_CDPE.pdf
   Google Scholar
• Green TC, Park JN, Gilbert M, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020;77:102661.
   PubMed Web of Science ®Google Scholar
• Maghsoudi N, McDonald K, Stefan C, Drug Checking Services in Toronto Working Group, et al. Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale. Harm Reduct J. 2020;17(1):9.
   PubMedGoogle Scholar
• McCrae K, Tobias S, Grant C, et al. Assessing the limit of detection of fourier-transform infrared spectroscopy and immunoassay strips for fentanyl in a real-world setting. Drug Alcohol Rev. 2020;39(1):98–102.
   PubMed Web of Science ®Google Scholar
• Ti L, Tobias S, Lysyshyn M, et al. Detecting fentanyl using point-of-care drug checking technologies: a validation study. Drug Alcohol Depend. 2020;212:108006.
   PubMed Web of Science ®Google Scholar
• Tupper KW, McCrae K, Garber I, et al. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242–245.
   PubMed Web of Science ®Google Scholar
• Bowles JM, McDonald K, Maghsoudi N, et al. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications. Harm Reduct J. 2021;18(1):104.
   PubMed Web of Science ®Google Scholar
• Laing MK, Ti L, Marmel A, et al. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: PReliminary results from a community drug checking program using point-of-care and confirmatory methods. Int J Drug Policy. 2021;93:103169.
   PubMed Web of Science ®Google Scholar
• Niles JK, Gudin J, Radcliff J, et al. The opioid epidemic within the COVID-19 pandemic: Drug testing in 2020. Popul Health Manag. 2021;24(S1):S43–S51.
   PubMedGoogle Scholar
• Morin KA, Acharya S, Eibl JK, et al. Evidence of increased fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada. Int J Drug Policy. 2021;90:103088.
   PubMedGoogle Scholar
• Pytell JD, Rastegar DA. Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic. J Subst Abuse Treat. 2021;120:108155.
   PubMed Web of Science ®Google Scholar
• Brett A, Foster H, Joseph M, et al. Patient-centered telehealth solution for observed urine collections in substance use disorder care delivery during COVID-19 and beyond. J Patient Exp. 2021;8:237437352110331.
   Google Scholar
• Warrington JS, Brett A, Foster H, et al. Driving access to care: Use of mobile units for urine specimen collection during the coronavirus disease-19 (COVID-19) pandemic. Acad Pathol. 2020;7:237428952095355.
   Google Scholar
• ASAM. Caring for patients during the COVID-19 pandemic: Adjusting drug testing protocols; 2020 [cited 2022 Jan 21]. Available from: https://sitefinitystorage.blob.core.windows.net/sitefinity-production-blobs/docs/default-source/guidelines/covid-19/11-adjusting-drug-testing-protocols_final.pdf?sfvrsn=5dba58c2_2
   Google Scholar
• Delaney SR, Danso D, Langman LJ, et al. Assessment of mass spectrometry-based pain management testing in clinical laboratories across North America. Clin Biochem. 2020;85:49–52.
   PubMedGoogle Scholar
• Elarabi HF, Shawky M, Mustafa N, et al. Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial. Addiction. 2021;116(9):2398–2408.
   PubMedGoogle Scholar
• Arthur J, Lu Z, Nguyen K, et al. Random vs targeted urine drug testing among patients undergoing long-term opioid treatment for cancer pain. JAMA Oncol. 2020;6(4):580–581.
   PubMedGoogle Scholar
• Wyse J, Simmons A, Ramachandran B, et al. "I don't mind doing what it takes to be safe." Patient perspectives of urine drug testing for pain. J Gen Intern Med. 2021;36(1):243–244.
   PubMedGoogle Scholar
• Krishnamurthy P, Ranganathan G, Williams C, et al. Impact of urine drug screening on no shows and dropouts among chronic pain patients: a propensity-matched cohort study. Pain Phys. 2016;19(2):89–100.
   PubMedGoogle Scholar
• Reisfield GM, Bertholf R, Barkin RL, et al. Urine drug test interpretation: what do physicians know? J Opioid Manag. 2007;3(2):80–86.
   PubMedGoogle Scholar
• Reisfield GM, Webb FJ, Bertholf RL, et al. Family physicians' proficiency in urine drug test interpretation. J Opioid Manag. 2007;3(6):333–337.
   PubMedGoogle Scholar
• Starrels JL, Fox AD, Kunins HV, et al. They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med. 2012;27(11):1521–1527.
   PubMed Web of Science ®Google Scholar
• Levy S, Harris SK, Sherritt L, et al. Drug testing of adolescents in ambulatory medicine: physician practices and knowledge. Arch Pediatr Adolesc Med. 2006;160(2):146–150.
   PubMedGoogle Scholar
• Rosenfeld B, Budescu DV, Han Y, et al. Does the perceived accuracy of urine drug testing impact clinical decision-making? Subst Abus. 2020;41(1):85–92.
   PubMed Web of Science ®Google Scholar
• Kirsh KL, Baxter LE, Rzetelny A, et al. A survey of ASAM members' knowledge, attitudes, and practices in urine drug testing. J Addict Med. 2015;9(5):399–404.
   PubMed Web of Science ®Google Scholar
• CAP. April 2021 urine drug screening (UDS-A) participant summary. College of American Pathologists; 2021. (Available only to participants.)
   Google Scholar
• Schmidt RL, Garcia CA, Panlener J, et al. An analysis of clinical consultation activities in clinical chemistry: implications for transformation and resident training in chemical pathology. Arch Pathol Lab Med. 2014; May138(5):671–677.
   PubMedGoogle Scholar
• Haidari M, Yared M, Olano JP, et al. Attitudes and beliefs of pathology residents regarding the subspecialty of clinical chemistry: Results of a survey. Arch Pathol Lab Med. 2017;141(2):203–208.
   PubMedGoogle Scholar
• Kass ME, Crawford JM, Bennett B, Future of Pathology Task Group, et al. Adequacy of pathology resident training for employment: a survey report from the future of pathology task group. Arch Pathol Lab Med. 2007;131(4):545–555.
   PubMedGoogle Scholar
• Horowitz RE. Expectations and essentials for the community practice of pathology. Hum Pathol. 2006;37(8):969–973.
   PubMedGoogle Scholar
• Kale N. Urine drug tests: ordering and interpreting results. Am Fam Physician. 2019;99(1):33–39.
   PubMedGoogle Scholar
• Salomone A, Palamar JJ. Toxicosurveillance of novel opioids: just screening tests may not be enough. Am J Drug Alcohol Abuse. 2021;47(3):271–272.
   PubMedGoogle Scholar
• Jung J, Kolodziej A, Pape E, et al. Multiplex detection of 14 fentanyl analogues and U-47700 in biological samples: application to a panel of French hospitalized patients. Forensic Sci Int. 2020;317:110437.
   PubMedGoogle Scholar
• Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th annual report. Clin Toxicol. 2020;58(12):1360–1541.
   PubMed Web of Science ®Google Scholar
• Horber S, Peter A, Lehmann R, et al. Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS/MS-based clinical analyzer suggests a new era in laboratory medicine. Clin Chem Lab Med. 2021;59(5):913–920.
   PubMedGoogle Scholar
• Gottardo R, Murari M, Bertaso A, et al. Drug screening by using the Toxtyper™ LC-ion trap MS: optimization of its application on serum samples in a DUID context. Clin Chim Acta. 2020;510:537–543.
   PubMedGoogle Scholar
• Kempf J, Traber J, Auwarter V, et al. 'Psychotropics caught in a trap' – adopting a screening approach to specific needs. Forensic Sci Int. 2014;243:84–89.
   PubMedGoogle Scholar
• Ott M, Berbalk K, Plecko T, et al. Detection of drugs of abuse in urine using the Bruker Toxtyper™: experiences in a routine clinical laboratory setting. Clin Mass Spectrom. 2017;4–5:11–18.
   Google Scholar
• Hughey JJ, Colby JM. Discovering cross-reactivity in urine drug screening immunoassays through large-scale analysis of electronic health records. Clin Chem. 2019;65(12):1522–1531.
   PubMed Web of Science ®Google Scholar
• Ayala-Lopez N, Aref L, Colby JM, et al. A computational approach to identify interfering medications on urine drug screening assays without data from confirmatory testing. J Anal Toxicol. 2021;45(4):325–330.
   PubMedGoogle Scholar
• Ayala-Lopez N, Colby JM, Hughey JJ. Analysis of electronic health records reveals medication-related interference on point-of-care urine drug screening assays. J Anal Toxicol. 2020. DOI:https://doi.org/10.1093/jat/bkaa179
   Google Scholar
• R Foundation for Statistical Computing. A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing; 2017 [cited 2021 21 November]. Available from: https://www.R-project.org/
   Google Scholar
• Warrington JS, Swanson K, Dodd M, et al. Measuring what matters: how the laboratory contributes value in the opioid crisis. J Appl Lab Med. 2020;5(6):1378–1390.
   PubMedGoogle Scholar
• Morrow JB, Ropero-Miller JD, Catlin ML, et al. The opioid epidemic: moving toward an integrated, holistic analytical response. J Anal Toxicol. 2019;43(1):1–9.
   PubMedGoogle Scholar
• Salvador J, Bhatt S, Fowler R, et al. Engagement with project ECHO to increase medication-assisted treatment in rural primary care. Psychiatr Serv. 2019;70(12):1157–1160.
   PubMed Web of Science ®Google Scholar
• Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (extension for community healthcare outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20–24.
   PubMed Web of Science ®Google Scholar
• Winstanley EL, Lander LR, Berry JH, et al. West Virginia's model of buprenorphine expansion: Preliminary results. J Subst Abuse Treat. 2020;108:40–47.
   PubMed Web of Science ®Google Scholar
• Health Canada. Communicating about substance use in compassionate, safe and non-stigmatizing ways; 2019 [cited 2022 Jan 21]. Availabe at: https://www.canada.ca/en/public-health/services/publications/healthy-living/communicating-about-substance-use-compassionate-safe-non-stigmatizing-ways-2019.html
   Google Scholar
• Rego X, Oliveira MJ, Lameira C, et al. 20 Years of portuguese drug policy - developments, challenges and the quest for human rights. Subst Abuse Treat Prev Policy. 2021;16(1):59.
   PubMedGoogle Scholar
• Lines R, Hannah J, Girelli G. Treatment in liberty’ human rights and compulsory detention for drug use. Human Rights Law Rev. 2022. DOI:https://doi.org/10.1093/hrlr/ngab022
   Google Scholar
• Csete J, Kamarulzaman A, Kazatchkine M, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427–1480.
   PubMed Web of Science ®Google Scholar
• Patrick SW, Richards MR, Dupont WD, et al. Association of pregnancy and insurance status with treatment access for opioid use disorder. JAMA Netw Open. 2020;3(8):e2013456.
   PubMed Web of Science ®Google Scholar
• Accurso AJ, Rastegar DA. The effect of a payer-mandated decrease in buprenorphine dose on aberrant drug tests and treatment retention among patients with opioid dependence. J Subst Abuse Treat. 2016;61:74–79.
   PubMed Web of Science ®Google Scholar
• Mark TL, Hinde JM, Zarkin GA, et al. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. J Subst Abuse Treat. 2020;116:108062.
   PubMed Web of Science ®Google Scholar